In Science Corporation’s BCI retinal implant trial, 84% of patients who had lost their sight to dry AMD could read letters, numbers and words using prosthetic vision.
Science Corporation, the neural engineering and brain-computer interface (BCI) company, today announced the European commercial launch of PRIMA, the first and only treatment shown in clinical trials ...